1
|
Aubin L, Vilas Boas R, Daltro De Oliveira R, Le Brun V, Divoux M, Rey J, Mansier O, Ianotto JC, Pastoret C, Desmares A, Murati A, de Mas V, Tavitian S, Girodon F, Soret Dulphy J, Maslah N, Goncalves Monteiro V, Boyer F, Orvain C, Ranta D, Cayssials É, Le Clech L, Nicol C, Rottier C, Botin Lopez T, Castel B, Rispal P, Beziat G, Bescond C, Laribi K, Benajiba L, Ugo V, Lippert E, Cottin L, Luque Paz D. CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM. Am J Hematol 2024; 99:1001-1004. [PMID: 38404143 DOI: 10.1002/ajh.27265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 02/08/2024] [Accepted: 02/13/2024] [Indexed: 02/27/2024]
Abstract
A low allele burden (i.e., <20%) of the CALR driver mutation is found in 10.8% of CALR-mutated MPNs, mostly in essential thrombocythemia, and correlates with a milder phenotype and a more indolent evolution compared to patients with an allele burden ≥20%.
Collapse
Affiliation(s)
- Laura Aubin
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
- Laboratoire d'Hématologie, CH St Malo, St Malo, France
- Laboratoire d'Hématologie, CHU Rennes, Rennes, France
| | | | | | | | - Marion Divoux
- Hématologie Clinique, CHU Nancy, Nancy, France
- Laboratoire d'Hématologie, CHU Nancy, Nancy, France
| | - Jérôme Rey
- Centre de Recherche en Cancérologie de Marseille (CRCM), Département d'Hématologie, Institut Paoli-Calmettes, CRCM, Inserm, Marseille, France
| | - Olivier Mansier
- Laboratoire d'Hématologie, CHU Bordeaux, Bordeaux, France
- Inserm U1034, Université de Bordeaux, Bordeaux, France
| | | | | | - Anne Desmares
- Laboratoire d'Hématologie, CHU Rennes, Rennes, France
| | - Anne Murati
- Centre de Recherche en Cancérologie de Marseille (CRCM), Département de Biopathologie et Département d'Oncologie Prédictive, Institut Paoli-Calmettes, Inserm, Marseille, France
| | - Véronique de Mas
- Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, CHU Toulouse, Toulouse, France
| | - Suzanne Tavitian
- Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, CHU Toulouse, Toulouse, France
| | | | - Juliette Soret Dulphy
- INSERM U944/CNRS UMR7212, Hôpital Saint Louis APHP, Université de Paris, Paris, France
| | - Nabih Maslah
- Laboratoire de Biologie Cellulaire, Université Paris Cité, APHP, Hôpital Saint-Louis, Paris, France
| | | | | | | | - Dana Ranta
- Hématologie Clinique, CHU Nancy, Nancy, France
| | - Émilie Cayssials
- Service d'Oncologie Hématologique et Thérapie Cellulaire, CHU de Poitiers, Poitiers, France
| | | | | | - Camille Rottier
- Laboratoire d'oncobiologie moléculaire, CHU Amiens-Picardie, Amiens, France
| | | | - Brice Castel
- Service de Médecine Interne, CH de Bigorre, Tarbes, France
| | | | | | | | - Kamel Laribi
- Hématologie Clinique, CH Le Mans, Le Mans, France
| | - Lina Benajiba
- INSERM U944/CNRS UMR7212, Hôpital Saint Louis APHP, Université de Paris, Paris, France
| | - Valérie Ugo
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
| | - Eric Lippert
- Laboratoire d'Hématologie, CHRU Brest, Brest, France
- INSERM, U1078, Université de Brest, Brest, France
| | - Laurane Cottin
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
| | - Damien Luque Paz
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
| |
Collapse
|
2
|
Luque Paz D, Chean D, Tattevin P, Luque Paz D, Bayeh BA, Kouatchet A, Douillet D, Riou J. Efficacy and safety of antibiotics targeting Gram-negative bacteria in nosocomial pneumonia: a systematic review and Bayesian network meta-analysis. Ann Intensive Care 2024; 14:66. [PMID: 38662091 PMCID: PMC11045692 DOI: 10.1186/s13613-024-01291-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Accepted: 04/06/2024] [Indexed: 04/26/2024] Open
Abstract
BACKGROUND Multiple randomized controlled studies have compared numerous antibiotic regimens, including new, recently commercialized antibiotics in the treatment of nosocomial pneumonia (NP). The objective of this Bayesian network meta-analysis (NMA) was to compare the efficacy and the safety of different antibiotic treatments for NP. METHODS We conducted a systematic search of PubMed, Medline, Web of Science, EMBASE and the Cochrane Library databases from 2000 through 2021. The study selection included studies comparing antibiotics targeting Gram-negative bacilli in the setting of NP. The primary endpoint was 28 day mortality. Secondary outcomes were clinical cure, microbiological cure and adverse events. RESULTS Sixteen studies encompassing 4993 patients were included in this analysis comparing 13 antibiotic regimens. The level of evidence for mortality comparisons ranged from very low to moderate. No significant difference in 28 day mortality was found among all beta-lactam regimens. Only the combination of meropenem plus aerosolized colistin was associated with a significant decrease of mortality compared to using intravenous colistin alone (OR = 0.43; 95% credible interval [0.17-0.94]), based on the results of the smallest trial included. The clinical failure rate of ceftazidime was higher than meropenem with (OR = 1.97; 95% CrI [1.19-3.45]) or without aerosolized colistin (OR = 1.40; 95% CrI [1.00-2.01]), imipemen/cilastatin/relebactam (OR = 1.74; 95% CrI [1.03-2.90]) and ceftazidime/avibactam (OR = 1.48; 95% CrI [1.02-2.20]). For microbiological cure, no substantial difference between regimens was found, but ceftolozane/tazobactam had the highest probability of being superior to comparators. In safety analyses, there was no significant difference between treatments for the occurrence of adverse events, but acute kidney failure was more common in patients receiving intravenous colistin. CONCLUSIONS This network meta-analysis suggests that most antibiotic regimens, including new combinations and cefiderocol, have similar efficacy and safety in treating susceptible Gram-negative bacilli in NP. Further studies are necessary for NP caused by multidrug-resistant bacteria. Registration PROSPERO CRD42021226603.
Collapse
Affiliation(s)
- David Luque Paz
- Infectious Diseases and Intensive Care Unit, Pontchaillou Hospital, University Hospital of Rennes, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France.
- Inserm U1230, Université de Rennes, Rennes, France.
| | - Dara Chean
- Intensive Care Unit, University Hospital of Angers, Angers, France
| | - Pierre Tattevin
- Infectious Diseases and Intensive Care Unit, Pontchaillou Hospital, University Hospital of Rennes, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France
- Inserm U1230, Université de Rennes, Rennes, France
| | - Damien Luque Paz
- Laboratory of Hematology, Angers University Hospital, Angers, France
- INSERM, CRCINA, University of Angers, Angers, France
| | - Betsega Assefa Bayeh
- Department of Pneumology and Respiratory Functional Exploration, University Hospital of Tours, Tours, France
| | | | - Delphine Douillet
- Emergency Department, Angers University Hospital, Angers, France
- University of Angers, UMR MitoVasc CNRS 6015 - INSERM 1083, Angers, France
- FCRIN, INNOVTE, Saint Etienne, France
| | - Jérémie Riou
- University of Angers, Inserm, CNRS, MINT, SFR ICAT, 49000, Angers, France
- Methodology and Biostatistics Department, Delegation to Clinical Research and Innovation, Angers University Hospital, Angers, France
| |
Collapse
|
3
|
Usart M, Stetka J, Luque Paz D, Hansen N, Kimmerlin Q, Almeida Fonseca T, Lock M, Kubovcakova L, Karjalainen R, Hao-Shen H, Börsch A, El Taher A, Schulz J, Leroux JC, Dirnhofer S, Skoda RC. Loss of Dnmt3a increased self-renewal and resistance to pegIFNα in JAK2-V617F-positive myeloproliferative neoplasms. Blood 2024:blood.2023020270. [PMID: 38493481 DOI: 10.1182/blood.2023020270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 02/23/2024] [Accepted: 02/26/2024] [Indexed: 03/19/2024] Open
Abstract
Pegylated interferon alpha (pegIFNα) can induce molecular remissions in JAK2-V617F-positive myeloproliferative neoplasms (MPN) patients by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal, such as DNMT3A, have been reported to have poorer responses to pegIFNα. We investigated if DNMT3A loss leads to alterations in JAK2-V617F LT-HSCs functions conferring resistance to pegIFNα treatment in a mouse model of MPN and in hematopoietic progenitors from MPN patients. Long-term treatment with pegIFNα normalized blood parameters, reduced splenomegaly and JAK2-V617F-chimerism in single-mutant JAK2-V617F (VF) mice. However, pegIFNα in VF;Dnmt3aΔ/Δ (VF;DmΔ/Δ) mice worsened splenomegaly and failed to reduce JAK2-V617F-chimerism. Furthermore, LT-HSCs from VF;DmΔ/Δ mice compared to VF were less prone to accumulate DNA damage and exit dormancy upon pegIFNα treatment. RNA-sequencing showed that IFNα induced stronger upregulation of inflammatory pathways in LT-HSCs from VF;DmΔ/Δ compared to VF mice, indicating that the resistance of VF;DmΔ/Δ LT-HSC was not due to failure in IFNα signaling. Transplantations of bone marrow from pegIFNα treated VF;DmΔ/Δ mice gave rise to more aggressive disease in secondary and tertiary recipients. Liquid cultures of hematopoietic progenitors from MPN patients with JAK2-V617F and DNMT3A mutation showed increased percentages of JAK2-V617F-positive colonies upon IFNα exposure, whereas in patients with JAK2-V617F alone the percentages of JAK2-V617F-positive colonies decreased or remained unchanged. PegIFNα combined with 5-azacytidine only partially overcame resistance in VF;DmΔ/Δ mice. However, this combination strongly decreased the JAK2-mutant allele burden in mice carrying VF mutation only, showing potential to inflict substantial damage preferentially to the JAK2-mutant clone.
Collapse
Affiliation(s)
- Marc Usart
- University Hospital Basel and University of Basel, Basel, Switzerland
| | - Jan Stetka
- University Hospital Basel and University of Basel, Switzerland, Basel, Switzerland
| | - Damien Luque Paz
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France, ANGERS, France
| | - Nils Hansen
- University Hospital of Basel, Basel, Switzerland
| | - Quentin Kimmerlin
- University Hospital Basel and University of Basel, Basel, Switzerland
| | | | - Melissa Lock
- University Hospital Basel and University of Basel, Switzerland, Basel, Switzerland
| | - Lucia Kubovcakova
- University Hospital Basel and University of Basel, Basel, Switzerland
| | - Riikka Karjalainen
- University Hospital Basel and University of Basel, Switzerland, Basel, Switzerland
| | - Hui Hao-Shen
- Swiss Institute of Bioinformatics, Basel, Switzerland, Switzerland
| | | | - Athimed El Taher
- University Hospital Basel and University of Basel, Basel, Switzerland
| | | | | | | | - Radek C Skoda
- University Hospital Basel and University of Basel, Basel, Switzerland
| |
Collapse
|
4
|
Rai S, Zhang Y, Grockowiak E, Kimmerlin Q, Hansen N, Stoll CB, Usart M, Luque Paz D, Hao-Shen H, Zhu Y, Roux J, Bader MS, Dirnhofer S, Farady CJ, Schroeder T, Méndez-Ferrer S, Skoda RC. IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv 2024; 8:1234-1249. [PMID: 38207211 PMCID: PMC10912850 DOI: 10.1182/bloodadvances.2023011338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Revised: 12/26/2023] [Accepted: 01/02/2024] [Indexed: 01/13/2024] Open
Abstract
ABSTRACT JAK 2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPNs. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that interleukin-1β (IL-1β)-mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations from JAK2-V617F and GFP transgenic (VF;GFP) mice that were further crossed with IL-1β-/- or IL-1R1-/- mice. To study the role of IL-1β and its receptor on monoclonal evolution of MPN, we performed competitive BM transplantations at high dilutions with only 1 to 3 hematopoietic stem cells (HSCs) per recipient. Loss of IL-1β in JAK2-mutant HSCs reduced engraftment, restricted clonal expansion, lowered the total numbers of functional HSCs, and decreased the rate of conversion to MPN. Loss of IL-1R1 in the recipients also lowered the conversion to MPN but did not reduce the frequency of engraftment of JAK2-mutant HSCs. Wild-type (WT) recipients transplanted with VF;GFP BM that developed MPNs had elevated IL-1β levels and reduced frequencies of mesenchymal stromal cells (MSCs). Interestingly, frequencies of MSCs were also reduced in recipients that did not develop MPNs, had only marginally elevated IL-1β levels, and displayed low GFP-chimerism resembling CHIP. Anti-IL-1β antibody preserved high frequencies of MSCs in VF;GFP recipients and reduced the rate of engraftment and the conversion to MPN. Our results identify IL-1β as a potential therapeutic target for preventing the transition from JAK2-V617F CHIP to MPNs.
Collapse
Affiliation(s)
- Shivam Rai
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Yang Zhang
- Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland
| | - Elodie Grockowiak
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
- Department of Hematology, University of Cambridge, Cambridge, United Kingdom
- National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge, United Kingdom
| | - Quentin Kimmerlin
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Nils Hansen
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Cedric B. Stoll
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Marc Usart
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Damien Luque Paz
- University of Angers, Nantes Université, CHU Angers, INSERM, CNRS, CRCI2NA, Angers, France
| | - Hui Hao-Shen
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Yexuan Zhu
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
- Department of Hematology, University of Cambridge, Cambridge, United Kingdom
- National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge, United Kingdom
| | - Julien Roux
- Department of Biomedicine, Bioinformatics core facility, University of Basel, Basel, Switzerland
- Swiss Institute of Bioinformatics, Basel, Switzerland
| | - Michael S. Bader
- Division of Hematology, University Hospital Basel, Basel, Switzerland
| | - Stefan Dirnhofer
- Department of Pathology, University Hospital Basel, Basel, Switzerland
| | | | - Timm Schroeder
- Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland
| | - Simón Méndez-Ferrer
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
- Department of Hematology, University of Cambridge, Cambridge, United Kingdom
- National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge, United Kingdom
| | - Radek C. Skoda
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland
| |
Collapse
|
5
|
Bauduin A, Demoy M, Genevieve F, Tuffigo M, Luque Paz D, Boussaroque A. Blood smear invaders: About a fatal case of bacteremia. Int J Lab Hematol 2024. [PMID: 38409950 DOI: 10.1111/ijlh.14256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 02/14/2024] [Indexed: 02/28/2024]
Affiliation(s)
- Aurélien Bauduin
- Laboratoire d'Hématologie Biologique, Centre Hospitalo-Universitaire, Angers, France
| | - Marine Demoy
- Laboratoire d'Hématologie Biologique, Centre Hospitalo-Universitaire, Angers, France
| | - Franck Genevieve
- Laboratoire d'Hématologie Biologique, Centre Hospitalo-Universitaire, Angers, France
| | - Marie Tuffigo
- Laboratoire d'Hématologie Biologique, Centre Hospitalo-Universitaire, Angers, France
| | - Damien Luque Paz
- Laboratoire d'Hématologie Biologique, Centre Hospitalo-Universitaire, Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
| | - Agathe Boussaroque
- Laboratoire d'Hématologie Biologique, Centre Hospitalo-Universitaire, Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
| |
Collapse
|
6
|
Galtier J, Drevon L, Le Bris Y, Giraudier S, Wemeau M, Legros L, Luque Paz D, Girodon F, Kiladjian JJ, Mesguich C, Parrens M, Mediavilla C, Roy L, Guy A, Mansier O, Ianotto JC, James C. Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs. Haematologica 2024. [PMID: 38328854 DOI: 10.3324/haematol.2023.284488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Indexed: 02/09/2024] Open
Abstract
Not available.
Collapse
Affiliation(s)
- Jean Galtier
- Service d'hématologie et thérapie cellulaire, CHU de Bordeaux.
| | - Louis Drevon
- Service d'hématologie clinique, Hôpital Saint-Louis, APHP
| | | | | | | | | | | | | | | | | | - Marie Parrens
- Service d'anatomie et cytologie pathologique, CHU de Bordeaux
| | | | - Lydia Roy
- Service d'Hématologie Clinique, Hôpital Universitaire Henri Mondor, AP-HP and Faculté de Santé, UPEC, Créteil
| | | | - Olivier Mansier
- Service d'hématologie biologique, CHU de Bordeaux, France; Univ. Bordeaux, INSERM, Biologie des maladies cardiovasculaires, U1034, F-33600 Pessac
| | | | - Chloe James
- Service d'hématologie biologique, CHU de Bordeaux, France; Univ. Bordeaux, INSERM, Biologie des maladies cardiovasculaires, U1034, F-33600 Pessac
| |
Collapse
|
7
|
Pasquer H, Daltro de Oliveira R, Vasseur L, Soret-Dulphy J, Maslah N, Zhao LP, Marcault C, Cazaux M, Gauthier N, Verger E, Parquet N, Vainchenker W, Raffoux E, Ugo V, Luque Paz D, Roy L, Lambert WC, Ianotto JC, Lippert E, Giraudier S, Cassinat B, Kiladjian JJ, Benajiba L. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification. Leukemia 2024; 38:326-339. [PMID: 38148396 DOI: 10.1038/s41375-023-02114-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 11/30/2023] [Accepted: 12/06/2023] [Indexed: 12/28/2023]
Abstract
Current recommended risk scores to predict thrombotic events associated with myeloproliferative neoplasms (MPN) do not discriminate between arterial and venous thrombosis despite their different physiopathology. To define novel stratification systems, we delineated a comprehensive landscape of MPN associated thrombosis across a large long-term follow-up MPN cohort. Prior arterial thrombosis, age >60 years, cardiovascular risk factors and presence of TET2 or DNMT3A mutations were independently associated with arterial thrombosis in multivariable analysis. ARTS, an ARterial Thrombosis Score, based on these four factors, defined low- (0.37% patients-year) and high-risk (1.19% patients-year) patients. ARTS performance was superior to the two-tiered conventional risk stratification in our training cohort, across all MPN subtypes, as well as in two external validation cohorts. Prior venous thrombosis and presence of a JAK2V617F mutation with a variant allelic frequency ≥50% were independently associated with venous thrombosis. The discrimination potential of VETS, a VEnous Thrombosis Score based on these two factors, was poor, similar to the two-tiered conventional risk stratification. Our study pinpoints arterial and venous thrombosis clinico-molecular differences and proposes an arterial risk score for more accurate patients' stratification. Further improvement of venous risk scores, accounting for additional factors and considering venous thrombosis as a heterogeneous entity is warranted.
Collapse
Affiliation(s)
- Hélène Pasquer
- Université Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France
- INSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France
| | - Rafael Daltro de Oliveira
- Université Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France
| | - Loic Vasseur
- Université Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France
| | - Juliette Soret-Dulphy
- Université Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France
| | - Nabih Maslah
- Université Paris Cité, APHP, Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris, France
- INSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France
| | - Lin-Pierre Zhao
- Université Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France
| | - Clémence Marcault
- Université Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France
| | - Marine Cazaux
- Université Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France
| | - Nicolas Gauthier
- Université Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France
| | - Emmanuelle Verger
- Université Paris Cité, APHP, Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris, France
- INSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France
| | - Nathalie Parquet
- Université Paris Cité, APHP, Hôpital Saint-Louis, Département d'hématologie et d'Immunologie, Paris, France
| | - William Vainchenker
- APHP, Hôpital Saint-Louis, Département d'hématologie et d'Immunologie, Paris, France
| | - Emmanuel Raffoux
- Université Paris Cité, APHP, Hôpital Saint-Louis, Département d'hématologie et d'Immunologie, Paris, France
| | - Valérie Ugo
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
| | - Damien Luque Paz
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
| | - Lydia Roy
- Université Paris Est Créteil, APHP, Hôpital Henri Mondor, Service d'hématologie, Créteil, France
| | - Wayne-Corentin Lambert
- Université de Bretagne Occidentale, CHU de Brest, Service d'Hématologie Biologique, Brest, France
| | - Jean-Christophe Ianotto
- Université de Bretagne Occidentale, CHU de Brest, Service d'Hématologie et d'Hémostase Clinique, Brest, France
| | - Eric Lippert
- Université de Bretagne Occidentale, CHU de Brest, Service d'Hématologie Biologique, Brest, France
| | - Stéphane Giraudier
- Université Paris Cité, APHP, Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris, France
- INSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France
| | - Bruno Cassinat
- Université Paris Cité, APHP, Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris, France
- INSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France
| | - Jean-Jacques Kiladjian
- Université Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France
- INSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France
| | - Lina Benajiba
- Université Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France.
- INSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France.
| |
Collapse
|
8
|
Darlington M, Sujobert P, Kosmider O, Luque Paz D, Kaltenbach S, Figeac M, Hayette S, Mezaour N, Coquerelle S, Alary AS, Bidet A, Le Bris Y, Delabesse E, Davi F, Preudhomme C, Durand-Zaleski I, Macintyre E, Alame M, Baran-Marzak F, Berger MG, Bories D, Caye-Eude A, Cayuela JM, Cornillet-Lefebvre P, Delhommeau F, Estienne-Felix MH, Etancelin P, Flandrin-Gresta P, Lippert E, Marzac C, Miguet L, Pastoret C, Raynaud S, Rizzo D. Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France. Hemasphere 2023; 7:e943. [PMID: 37637995 PMCID: PMC10455455 DOI: 10.1097/hs9.0000000000000943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Accepted: 07/18/2023] [Indexed: 08/29/2023] Open
Abstract
The objective of this study was to assess the clinical impact and financial costs of next-generation sequencing (NGS) in 5 categories of pediatric and adult hematological cancers. NGS prescriptions were prospectively collected from 26 laboratories, with varied technical and reporting practice (all or only significant targets). Impact was defined by the identification of (1) an actionable mutation, (2) a mutation with prognostic and/or theranostic value, and/or (3) a mutation allowing nosological refinement, reported by local investigators. A microcosting study was undertaken in 4 laboratories, identifying the types and volumes of resources required for each procedural step. Individual index prescriptions for 3961 patients were available for impact analysis on the management of myeloid disorders (two thirds) and, mainly mature B, lymphoid disorders (one third). NGS results were considered to impact the management for 73.4% of prescriptions: useful for evaluation of prognostic risk in 34.9% and necessary for treatment adaptation (actionable) in 19.6%, but having no immediate individual therapeutic impact in 18.9%. The average overall cost per sample was 191 € for the restricted mature lymphoid amplicon panel. Capture panel costs varied from 369 € to 513 €. Unit costs varied from 0.5 € to 5.7 € per kb sequenced, from 3.6 € to 11.3 € per target gene/hot-spot sequenced and from 4.3 € to 73.8 € per target gene/hot-spot reported. Comparable costs for the Amplicon panels were 5-8 € per kb and 10.5-14.7 € per target gene/hot-spot sequenced and reported, demonstrating comparable costs with greater informativity/flexibility for capture strategies. Sustainable funding of precision medicine requires a transparent discussion of its impact on care pathways and its financial aspects.
Collapse
Affiliation(s)
- Meryl Darlington
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
| | - Pierre Sujobert
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
| | - Olivier Kosmider
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
| | - Damien Luque Paz
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
| | - Sophie Kaltenbach
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
| | - Martin Figeac
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
| | - Sandrine Hayette
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
| | - Nadia Mezaour
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
| | - Séverine Coquerelle
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
| | - Anne-Sophie Alary
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
| | - Audrey Bidet
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
| | - Yannick Le Bris
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
| | - Eric Delabesse
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
| | - Frédéric Davi
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
| | - Claude Preudhomme
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
| | | | - Elizabeth Macintyre
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Université Paris Cité, CNRS, Inserm, France
| | - Mélissa Alame
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Fanny Baran-Marzak
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Marc G. Berger
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Dominique Bories
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Aurélie Caye-Eude
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Jean-Michel Cayuela
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Pascale Cornillet-Lefebvre
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - François Delhommeau
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Marie-Hélène Estienne-Felix
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Pascaline Etancelin
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Pascale Flandrin-Gresta
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Eric Lippert
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Christophe Marzac
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Laurent Miguet
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Cédric Pastoret
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - Sophie Raynaud
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| | - David Rizzo
- DRCI‑URC Eco Ile‑de‑France, Assistance Publique-Hôpitaux de Paris (AP-HP), France
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’hématologie biologique, France
- Hôpital Cochin, Hématologie Biologique, AP-HP, Université, Paris Cité, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, France
- Hématologie Biologique, AP-HP, Necker-Enfants Malades Hospital, Paris, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France
- CHU de Lille, Equipe bioinfo du Plateau Commun de Biologie Moléculaire, Lille, France
- Department of Hematology Biology, Molecular Hematology, Bordeaux University Hospital, Haut-Levêque Hospital, Pessac, France
- Hématologie Biologique, Nantes University Hospital and CRCI2NA Nantes-Angers, France
- Hématologie Biologique, CHU Toulouse, Inserm 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, France
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne University, Paris
- Université Paris Cité, CNRS, Inserm, France
| |
Collapse
|
9
|
Luque Paz D, Bader MS, Nienhold R, Rai S, Almeida Fonseca T, Stetka J, Hao-Shen H, Mild-Schneider G, Passweg JR, Skoda RC. Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms. Hemasphere 2023; 7:e885. [PMID: 37153874 PMCID: PMC10158927 DOI: 10.1097/hs9.0000000000000885] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Accepted: 03/31/2023] [Indexed: 05/10/2023] Open
Abstract
Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal architecture of their hematopoiesis by sequencing DNA from single-cell-derived colonies. In 22 of these patients, the same blood samples were also studied for comparison by Tapestri single-cell DNA sequencing (scDNAseq). The clonal architectures derived by the 2 methods showed good overall concordance. scDNAseq showed higher sensitivity for mutations with low variant allele fraction, but had more difficulties distinguishing between heterozygous and homozygous mutations. By unsupervised analysis of clonal architecture data from all 50 MPN patients, we defined 4 distinct clusters. Cluster 4, characterized by more complex subclonal structure correlated with reduced overall survival, independent of the MPN subtype, presence of high molecular risk mutations, or the age at diagnosis. Cluster 1 was characterized by additional mutations residing in clones separated from the JAK2-V617F clone. The correlation with overall survival improved when mutation in such separated clones were not counted. Our results show that scDNAseq can reliably decipher the clonal architecture and can be used to refine the molecular prognostic stratification that until now was primarily based on the clinical and laboratory parameters.
Collapse
Affiliation(s)
- Damien Luque Paz
- Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
| | | | - Ronny Nienhold
- Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland
| | - Shivam Rai
- Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland
| | - Tiago Almeida Fonseca
- Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland
| | - Jan Stetka
- Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland
| | - Hui Hao-Shen
- Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland
| | - Gabriele Mild-Schneider
- Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland
| | | | - Radek C. Skoda
- Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland
| |
Collapse
|
10
|
Luque Paz D, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood 2023; 141:1909-1921. [PMID: 36347013 PMCID: PMC10646774 DOI: 10.1182/blood.2022017578] [Citation(s) in RCA: 23] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 11/03/2022] [Accepted: 11/03/2022] [Indexed: 11/11/2022] Open
Abstract
BCR::ABL1-negative myeloproliferative neoplasms (MPNs) are clonal diseases originating from a single hematopoietic stem cell that cause excessive production of mature blood cells. The 3 subtypes, that is, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are diagnosed according to the World Health Organization (WHO) and international consensus classification (ICC) criteria. Acquired gain-of-function mutations in 1 of 3 disease driver genes (JAK2, CALR, and MPL) are the causative events that can alone initiate and promote MPN disease without requiring additional cooperating mutations. JAK2-p.V617F is present in >95% of PV patients, and also in about half of the patients with ET or PMF. ET and PMF are also caused by mutations in CALR or MPL. In ∼10% of MPN patients, those referred to as being "triple negative," none of the known driver gene mutations can be detected. The common theme between the 3 driver gene mutations and triple-negative MPN is that the Janus kinase-signal transducer and activator of transcription (JAK/STAT) signaling pathway is constitutively activated. We review the recent advances in our understanding of the early events after the acquisition of a driver gene mutation. The limiting factor that determines the frequency at which MPN disease develops with a long latency is not the acquisition of driver gene mutations, but rather the expansion of the clone. Factors that control the conversion from clonal hematopoiesis to MPN disease include inherited predisposition, presence of additional mutations, and inflammation. The full extent of knowledge of the mutational landscape in individual MPN patients is now increasingly being used to predict outcome and chose the optimal therapy.
Collapse
Affiliation(s)
- Damien Luque Paz
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
| | - Robert Kralovics
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
| | - Radek C. Skoda
- Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland
| |
Collapse
|
11
|
Bachelot A, Bouvier A, Riou J, Thepot S, Giltat A, Gomes CN, Paillassa J, Jouanneau-Courville R, Renard M, Beucher A, Cottin L, Wiber M, Ribourtout B, Geneviève F, Paz DL, Tanguy-Schmidt A, Ugo V, Hunault-Berger M, Blanchet O, Orvain C. Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: assessment of different risk scores. Am J Hematol 2023; 98:922-931. [PMID: 36964937 DOI: 10.1002/ajh.26917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Revised: 03/03/2023] [Accepted: 03/21/2023] [Indexed: 03/27/2023]
Abstract
The aim of this study was to evaluate how comorbidities and molecular landscape relate to outcome in patients with acute myeloid leukemia (AML) aged 60 years or older who received intensive induction therapy. In 91 patients, 323 mutations were identified in 77 genes by next-generation sequencing, with a median of four mutations per patient, with NPM1, FLT3, TET2, and DNMT3A being the most frequently mutated genes. A multistate model identified FLT3, IDH2, RUNX1, and TET2 mutations as associated with a higher likelihood of achieving complete remission while STAG2 mutations were associated with primary refractory disease, and DNMT3A, FLT3, IDH2, and TP53 mutations with mortality after relapse. Ferrara unfitness criteria and performance status were the best predictors of short-term outcome (AUC=82 for 2-month survival for both parameters), whereas genomic classifications better predicted long-term outcome, with the Patel risk stratification performing the best over the 5-year follow-up period (C-index=0.63 for event-free and overall survival). We show that most genomic prognostic classifications, mainly used in younger patients, are useful for classifying older patients, but to a lesser extent, because of different mutational profiles. Specific prognostic classifications, incorporating performance status, comorbidities, and cytogenetic/molecular data, should be specifically designed for patients over 60 years. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Amélie Bachelot
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Anne Bouvier
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Jérémie Riou
- MINT, UMR INSERM, 1066, CNRS 6021, Université d'Angers
| | - Sylvain Thepot
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Maladies du Sang, CHU d'Angers, Angers, France
| | - Aurélien Giltat
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Maladies du Sang, CHU d'Angers, Angers, France
| | - Christopher Nunes Gomes
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Maladies du Sang, CHU d'Angers, Angers, France
| | - Jérôme Paillassa
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Maladies du Sang, CHU d'Angers, Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France
| | - Rébecca Jouanneau-Courville
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Maxime Renard
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Annaelle Beucher
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Laurane Cottin
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France
| | - Margaux Wiber
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Bénédicte Ribourtout
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Franck Geneviève
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Damien Luque Paz
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France
| | - Aline Tanguy-Schmidt
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Maladies du Sang, CHU d'Angers, Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France
| | - Valérie Ugo
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France
| | - Mathilde Hunault-Berger
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Maladies du Sang, CHU d'Angers, Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France
| | - Odile Blanchet
- CHU Angers, Laboratoire d'Hématologie, F-49000, Angers, France
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France
- Centre de Ressources Biologiques, BB-0033-00038, CHU d'Angers, Angers, France
| | - Corentin Orvain
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
- Maladies du Sang, CHU d'Angers, Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France
| |
Collapse
|
12
|
Rai S, Grockowiak E, Hansen N, Luque Paz D, Stoll CB, Hao-Shen H, Mild-Schneider G, Dirnhofer S, Farady CJ, Méndez-Ferrer S, Skoda RC. Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nat Commun 2022; 13:5346. [PMID: 36100613 PMCID: PMC9470591 DOI: 10.1038/s41467-022-32927-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Accepted: 08/24/2022] [Indexed: 12/17/2022] Open
Abstract
Interleukin-1β (IL-1β) is a master regulator of inflammation. Increased activity of IL-1β has been implicated in various pathological conditions including myeloproliferative neoplasms (MPNs). Here we show that IL-1β serum levels and expression of IL-1 receptors on hematopoietic progenitors and stem cells correlate with JAK2-V617F mutant allele fraction in peripheral blood of patients with MPN. We show that the source of IL-1β overproduction in a mouse model of MPN are JAK2-V617F expressing hematopoietic cells. Knockout of IL-1β in hematopoietic cells of JAK2-V617F mice reduces inflammatory cytokines, prevents damage to nestin-positive niche cells and reduces megakaryopoiesis, resulting in decrease of myelofibrosis and osteosclerosis. Inhibition of IL-1β in JAK2-V617F mutant mice by anti-IL-1β antibody also reduces myelofibrosis and osteosclerosis and shows additive effects with ruxolitinib. These results suggest that inhibition of IL-1β with anti-IL-1β antibody alone or in combination with ruxolitinib could have beneficial effects on the clinical course in patients with myelofibrosis.
Collapse
Affiliation(s)
- Shivam Rai
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, 4031, Basel, Switzerland
| | - Elodie Grockowiak
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, CB2 0AW, UK
- Department of Hematology, University of Cambridge, Cambridge, CB2 0AW, UK
- National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge, CB2 0AW, UK
| | - Nils Hansen
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, 4031, Basel, Switzerland
| | - Damien Luque Paz
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, 4031, Basel, Switzerland
| | - Cedric B Stoll
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, 4031, Basel, Switzerland
| | - Hui Hao-Shen
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, 4031, Basel, Switzerland
| | - Gabriele Mild-Schneider
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, 4031, Basel, Switzerland
| | - Stefan Dirnhofer
- Department of Pathology, University Hospital Basel, 4031, Basel, Switzerland
| | | | - Simón Méndez-Ferrer
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, CB2 0AW, UK
- Department of Hematology, University of Cambridge, Cambridge, CB2 0AW, UK
- National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge, CB2 0AW, UK
| | - Radek C Skoda
- Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, 4031, Basel, Switzerland.
| |
Collapse
|
13
|
Lemoine S, Mornet C, Quintin-Roue I, Rousselet MC, Cottin L, Georgeais A, Dubouis L, Boyer F, Orvain C, Caillon C, Renard M, Le Brun V, Le Clech L, Ianotto JC, Génin E, Burroni B, Ugo V, Paz DL, Lippert E. Histological, genetic characterization and follow-up of 130 patients with chronic triplenegative thrombocytosis. Haematologica 2022; 107:2725-2731. [PMID: 35833299 PMCID: PMC9614530 DOI: 10.3324/haematol.2022.280917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Indexed: 11/29/2022] Open
Affiliation(s)
- Sandrine Lemoine
- Laboratoire d'Hématologie, CHU Angers, Angers, France; Université d'Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA, Angers, France; Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; France Intergroupe des Syndromes Myéloprolifératifs (FIM)
| | - Clelia Mornet
- France Intergroupe des Syndromes Myéloprolifératifs (FIM); Laboratoire d'Hématologie, CHRU Brest, Brest
| | | | | | - Laurane Cottin
- Laboratoire d'Hématologie, CHU Angers, Angers, France; Université d'Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA, Angers, France; Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; France Intergroupe des Syndromes Myéloprolifératifs (FIM)
| | | | | | - Françoise Boyer
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; France Intergroupe des Syndromes Myéloprolifératifs (FIM); Service des Maladies du Sang, CHU Angers, Angers
| | - Corentin Orvain
- Université d'Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA, Angers, France; Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; France Intergroupe des Syndromes Myéloprolifératifs (FIM); Service des Maladies du Sang, CHU Angers, Angers
| | - Clara Caillon
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; Service des Maladies du Sang, CHU Angers, Angers
| | - Maxime Renard
- Laboratoire d'Hématologie, CHU Angers, Angers, France; Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL)
| | - Valoris Le Brun
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; Laboratoire d'Hématologie, CHRU Brest, Brest
| | | | - Jean-Christophe Ianotto
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; France Intergroupe des Syndromes Myéloprolifératifs (FIM); Service d'Hématologie Clinique, CHRU Brest, Brest, France; Univ Brest, Inserm, GETBO, Brest
| | | | - Barbara Burroni
- France Intergroupe des Syndromes Myéloprolifératifs (FIM); Service de pathologie, AP-HP, Hôpital Cochin, F-75014 Paris, France; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Paris
| | - Valérie Ugo
- Laboratoire d'Hématologie, CHU Angers, Angers, France; Université d'Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA, Angers, France; Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; France Intergroupe des Syndromes Myéloprolifératifs (FIM)
| | - Damien Luque Paz
- Laboratoire d'Hématologie, CHU Angers, Angers, France; Université d'Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA, Angers, France; Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; France Intergroupe des Syndromes Myéloprolifératifs (FIM)
| | - Eric Lippert
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; France Intergroupe des Syndromes Myéloprolifératifs (FIM); Laboratoire d'Hématologie, CHRU Brest, Brest, France; Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest
| |
Collapse
|
14
|
Sureau L, Buors C, Ianotto JC, Boyer F, Tanguy-Schmidt A, Roy L, Cayssials E, Cailly L, Chomel JC, Chauveau A, Orvain C, Mansier O, Ranta D, Robles M, Gyan E, Hérault O, Nimubona S, Marchand T, Lippert E, Riou J, Ugo V, Luque Paz D. JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes. Blood Cancer J 2022; 12:56. [PMID: 35395836 PMCID: PMC8993923 DOI: 10.1038/s41408-022-00646-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 03/08/2022] [Accepted: 03/09/2022] [Indexed: 11/09/2022] Open
Affiliation(s)
- Léa Sureau
- CHU Angers, Laboratoire d'Hématologie, Angers, France.,Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France.,Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France
| | - Caroline Buors
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Brest, Laboratoire d'Hématologie, Brest, France
| | - Jean-Christophe Ianotto
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Brest, Service d'Hématologie Clinique, Brest, France
| | - Françoise Boyer
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Angers, Service des Maladies du Sang, Angers, France
| | - Aline Tanguy-Schmidt
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France.,Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Angers, Service des Maladies du Sang, Angers, France
| | - Lydia Roy
- Hôpital Universitaire Henri Mondor, Service Hématologie Clinique, APHP & UPEC, UFR de Santé, Créteil, France
| | - Emilie Cayssials
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Poitiers, Service d'Oncologie Hématologique et Thérapie Cellulaire, Poitiers, France
| | - Laura Cailly
- CHU Poitiers, Service d'Oncologie Hématologique et Thérapie Cellulaire, Poitiers, France
| | - Jean-Claude Chomel
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Poitiers, Service de Cancérologie Biologique, Poitiers, France
| | | | - Corentin Orvain
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France.,Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Angers, Service des Maladies du Sang, Angers, France
| | - Olivier Mansier
- CHU de Bordeaux, Laboratoire d'Hématologie et Université de Bordeaux, Inserm U1034, Bordeaux, France
| | - Dana Ranta
- CHU Nancy, Hématologie Clinique, Nancy, France
| | - Margot Robles
- CH Périgueux, Hématologie Clinique, Périgueux, France
| | - Emmanuel Gyan
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Tours, Service d'Hématologie et Thérapie Cellulaire, CNRS EMR 7001 LNOx, université de Tours EA7501, Tours, France
| | - Olivier Hérault
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Tours, Service d'Hématologie Biologique, CNRS EMR 7001 LNOx, université de Tours EA7501, Tours, France
| | - Stanislas Nimubona
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Rennes, Service d'Hématologie Clinique, Rennes, France
| | - Tony Marchand
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Rennes, Service d'Hématologie Clinique, Rennes, France.,INSERM U1236, Faculté de Médecine, Université Rennes 1, Rennes, France
| | - Eric Lippert
- Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.,CHU Brest, Laboratoire d'Hématologie, Brest, France
| | - Jérémie Riou
- CHU Angers, Département de Biostatistiques et de Méthodologie, DRCI, Angers, France.,Univ Angers, CHU Angers, Inserm, CNRS, MINT, SFR ICAT, Angers, France
| | - Valérie Ugo
- CHU Angers, Laboratoire d'Hématologie, Angers, France. .,Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France. .,Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
| | - Damien Luque Paz
- CHU Angers, Laboratoire d'Hématologie, Angers, France. .,Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France. .,Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
| |
Collapse
|
15
|
Luque Paz D, Cottin L, Lippert E, Robin JB, Bescond C, Genevieve F, Boyer F, Quintin-Roue I, Rousselet MC, Burroni B, Hunault-Berger M, Ugo V, Ianotto JC, Orvain C. Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic/early primary myelofibrosis, and overt primary myelofibrosis. Ann Hematol 2021; 101:893-896. [PMID: 34611719 DOI: 10.1007/s00277-021-04672-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Accepted: 09/19/2021] [Indexed: 10/20/2022]
Affiliation(s)
- Damien Luque Paz
- Laboratoire d'Hématologie, CHU d'Angers, 49000, Angers, France.,Inserm, CRCINA, Univ Angers, Angers, France.,Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, FHU-GOAL, Angers, France
| | - Laurane Cottin
- Laboratoire d'Hématologie, CHU d'Angers, 49000, Angers, France.,Inserm, CRCINA, Univ Angers, Angers, France.,Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, FHU-GOAL, Angers, France
| | - Eric Lippert
- Laboratoire d'Hématologie, CHRU de Brest, Brest, France
| | - Jean-Baptiste Robin
- Service des Maladies du Sang, CHU d'Angers, 4 rue Larrey, 49933 Cedex 9, Angers, France
| | - Charles Bescond
- Service des Maladies du Sang, CHU d'Angers, 4 rue Larrey, 49933 Cedex 9, Angers, France
| | | | - Françoise Boyer
- Service des Maladies du Sang, CHU d'Angers, 4 rue Larrey, 49933 Cedex 9, Angers, France
| | | | | | | | - Mathilde Hunault-Berger
- Inserm, CRCINA, Univ Angers, Angers, France.,Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, FHU-GOAL, Angers, France.,Service des Maladies du Sang, CHU d'Angers, 4 rue Larrey, 49933 Cedex 9, Angers, France
| | - Valérie Ugo
- Laboratoire d'Hématologie, CHU d'Angers, 49000, Angers, France.,Inserm, CRCINA, Univ Angers, Angers, France.,Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, FHU-GOAL, Angers, France
| | - Jean-Christophe Ianotto
- Service d'Hématologie Clinique, Institut de Cancéro-Hématologie, CHRU de Brest, Brest, France
| | - Corentin Orvain
- Inserm, CRCINA, Univ Angers, Angers, France. .,Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, FHU-GOAL, Angers, France. .,Service des Maladies du Sang, CHU d'Angers, 4 rue Larrey, 49933 Cedex 9, Angers, France.
| |
Collapse
|
16
|
Lazarian G, Munger M, Quinquenel A, Dilhuydy M, Veronese L, Luque Paz D, Guièze R, Ledoux‐Pilon A, Paillassa J, Merabet F, Vial J, Bidet A, Waultier Rascalou A, Broseus J, Roos‐Weil D, Lavaud A, Molina L, Laribi K, Hivert B, Friedrich C, Carpentier B, Ysebaert L, Van Den Neste E, Willems L, Corby A, Poulain S, Eclache V, Maubec E, Martin A, Feugier P, Delmer A, Baran‐Marszak F, Leprêtre S, Cymbalista F. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO). Am J Hematol 2021; 96:E353-E356. [PMID: 34152612 DOI: 10.1002/ajh.26274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Accepted: 06/12/2021] [Indexed: 11/09/2022]
Affiliation(s)
- Grégory Lazarian
- Laboratoire d'hématologie Hôpital Avicenne ‐ INSERM U978‐ Université Paris Sorbonne Nord Bobigny France
| | - Michaël Munger
- Hématologie CHU de Québec ‐ Hôpital de l'Enfant‐Jésus Québec City Québec Canada
| | - Anne Quinquenel
- Service d'hématologie CHU de Reims, Hôpital Robert‐Debré, Université Reims Champagne‐Ardenne Reims France
| | - Marie‐Sarah Dilhuydy
- Service d'hématologie clinique et thérapie cellulaire CHU Bordeaux – Groupe Sud (Hôpital Haut‐Lévèque) Bordeaux France
| | - Lauren Veronese
- Cytogénétique Médicale Hématologie‐Oncologie, CHU Estaing Clermont‐Ferrand France
| | | | - Romain Guièze
- Service de thérapie cellulaire et hématologie clinique CHU de Clermont Ferrand Clermont‐Ferrand France
| | | | | | - Fatiha Merabet
- Service d'hématologie Hôpital de Versailles, Université Versailles Saint Quentin France
| | - Jean‐Philippe Vial
- Laboratoire d'hématologie CHU Bordeaux – Groupe Sud (Hôpital Haut‐Lévèque) Bordeaux France
| | - Audrey Bidet
- Laboratoire d'hématologie CHU Bordeaux – Groupe Sud (Hôpital Haut‐Lévèque) Bordeaux France
| | | | - Julien Broseus
- Laboratoire d'hématologie CHRU de Nancy Vandoeuvre‐lès‐Nancy France
| | - Damien Roos‐Weil
- Sorbonne Université, Service d'hématologie clinique, GH Pitie‐ Salpêtrière Paris France
| | - Anne Lavaud
- Sorbonne Université, Service d'hématologie clinique, GH Pitie‐ Salpêtrière Paris France
| | | | | | - Bénédicte Hivert
- Hématologie clinique Groupement des Hôpitaux de l'Institut Catholique de Lille Hôpital St Vincent de Paul Lille France
| | | | | | - Loïc Ysebaert
- Hématologie clinique Institut Universitaire du Cancer de Toulouse (IUCT) – Oncopole Toulouse France
| | | | - Lise Willems
- Hématologie clinique Hôpital Cochin Paris France
| | - Anne Corby
- Service d'oncologie hématologie Groupe hospitalier la Rochelle Hématologie Adulte La Rochelle France
| | - Stéphanie Poulain
- Hematology Laboratory, Biology and Pathology Center CHU de Lille Lille France
| | - Virginie Eclache
- Laboratoire d'hématologie Hôpital Avicenne ‐ INSERM U978‐ Université Paris Sorbonne Nord Bobigny France
| | - Eve Maubec
- Service de Dermatologie Hôpital Avicenne Bobigny France
| | - Antoine Martin
- Laboratoire d'anatomocytopathologie Hôpital Avicenne Bobigny France
| | - Pierre Feugier
- Département d'hématologie CHRU de Nancy Vandoeuvre‐lès‐Nancy France
| | - Alain Delmer
- Service d'hématologie CHU de Reims, Hôpital Robert‐Debré, Université Reims Champagne‐Ardenne Reims France
| | - Fanny Baran‐Marszak
- Laboratoire d'hématologie Hôpital Avicenne ‐ INSERM U978‐ Université Paris Sorbonne Nord Bobigny France
| | - Stéphane Leprêtre
- Département d'Hématologie Centre Henri Becquerel, Normandie université UNIROUEN Rouen France
| | - Florence Cymbalista
- Laboratoire d'hématologie Hôpital Avicenne ‐ INSERM U978‐ Université Paris Sorbonne Nord Bobigny France
| |
Collapse
|
17
|
Lemoine S, Renard M, Bouvier A, Orvain C, Giltat A, Cottin L, Blanchet O, Hunault-Berger M, Ugo V, Luque Paz D. No detection of atypical one-base deletion of CALR exon 9 with fragment analysis: A molecular trap to avoid. Blood Cells Mol Dis 2021; 90:102589. [PMID: 34214802 DOI: 10.1016/j.bcmd.2021.102589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Accepted: 06/18/2021] [Indexed: 11/19/2022]
Affiliation(s)
- Sandrine Lemoine
- Univ Angers, Inserm, CRCINA, F-49000 Angers, France; CHU Angers, Laboratoire d'hématologie, F-49000 Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France.
| | - Maxime Renard
- Univ Angers, Inserm, CRCINA, F-49000 Angers, France; CHU Angers, Laboratoire d'hématologie, F-49000 Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France
| | - Anne Bouvier
- Univ Angers, Inserm, CRCINA, F-49000 Angers, France; CHU Angers, Laboratoire d'hématologie, F-49000 Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France
| | - Corentin Orvain
- Univ Angers, Inserm, CRCINA, F-49000 Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France; CHU Angers, Service des maladies du sang, Angers, France
| | - Aurélien Giltat
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France; CHU Angers, Service des maladies du sang, Angers, France
| | - Laurane Cottin
- Univ Angers, Inserm, CRCINA, F-49000 Angers, France; CHU Angers, Laboratoire d'hématologie, F-49000 Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France
| | - Odile Blanchet
- Univ Angers, Inserm, CRCINA, F-49000 Angers, France; CHU Angers, Laboratoire d'hématologie, F-49000 Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France; CHU Angers, Centre de Ressources Biologiques, BB-0033-00038, Angers, France
| | - Mathilde Hunault-Berger
- Univ Angers, Inserm, CRCINA, F-49000 Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France; CHU Angers, Service des maladies du sang, Angers, France
| | - Valérie Ugo
- Univ Angers, Inserm, CRCINA, F-49000 Angers, France; CHU Angers, Laboratoire d'hématologie, F-49000 Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France
| | - Damien Luque Paz
- Univ Angers, Inserm, CRCINA, F-49000 Angers, France; CHU Angers, Laboratoire d'hématologie, F-49000 Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France
| |
Collapse
|
18
|
Vantyghem S, Peterlin P, Thépot S, Ménard A, Dubruille V, Debord C, Guillaume T, Garnier A, Le Bourgeois A, Wuilleme S, Godon C, Theisen O, Eveillard M, Delaunay J, Maisonneuve H, Morineau N, Villemagne B, Vigouroux S, Subiger F, Lestang E, Loirat M, Parcelier A, Godmer P, Mercier M, Trebouet A, Luque Paz D, Le Calloch R, Le Clech L, Bossard C, Moreau A, Ugo V, Hunault M, Moreau P, Le Gouill S, Chevallier P, Béné MC, Le Bris Y. Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. Haematologica 2021; 106:701-707. [PMID: 32241844 PMCID: PMC7927891 DOI: 10.3324/haematol.2019.242677] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Indexed: 12/15/2022] Open
Abstract
Next-generation sequencing (NGS) is used to investigate the presence of somatic mutations. The utility of incorporating routine sequencing to guide diagnosis and therapeutic decisions remains unclear. We report the findings of an observational, multicenter study that aimed to assess the impact of somatic mutation testing by NGS in a reallife setting of chronic myeloid malignancies. A total of 177 patients were enrolled, partitioned into two overlapping groups. In group A (n=94), the indication was to search for clonal hematopoiesis, in a context of suspected myelodysplastic syndrome or myeloproliferative neoplasia. In group B (n=95), the theranostic impact of somatic mutations was studied. A panel of 34 genes was used on DNA extracted from blood or bone marrow samples. Within group A, the detection of clonal hematopoiesis supported the diagnosis of chronic myeloid malignancies for 31 patients while the absence of clonal hematopoiesis ruled out the suspected diagnosis in 47 patients. Within group B, NGS identified prognostically relevant somatic mutations in 32 patients, which had a therapeutic impact in 18 cases. By determining the presence or absence of somatic mutations, the application of NGS in daily practice was found to be useful for an integrated final diagnosis in 83% of the patients. Moreover, the search for somatic mutations had a prognostic impact that led to treatment modification in 19% of the cases. This study outlines the fact that adequate implementation of new investigations may have a significant positive medico-economic impact by enabling appropriate management of patients.
Collapse
Affiliation(s)
| | | | - Sylvain Thépot
- Hematology Clinic, Angers University Hospital, Angers,CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Pays de la Loire
| | - Audrey Ménard
- Hematology Biology, Nantes University Hospital, Nantes
| | | | | | | | - Alice Garnier
- Hematology Clinic, Nantes University Hospital, Nantes
| | | | | | | | | | - Marion Eveillard
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Pays de la Loire,Hematology Biology, Nantes University Hospital, Nantes
| | | | | | | | | | | | | | - Elsa Lestang
- Hematology Clinic, Saint Nazaire Hospital, Saint Nazaire
| | - Marion Loirat
- Hematology Clinic, Saint Nazaire Hospital, Saint Nazaire
| | | | - Pascal Godmer
- Hematology Clinic, Bretagne Atlantique Hospital, Vannes
| | | | | | - Damien Luque Paz
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Pays de la Loire,Hematology Biology, Angers University Hospital, Angers
| | | | | | - Céline Bossard
- Pathology Department, Nantes University Hospital, Nantes, France
| | - Anne Moreau
- Pathology Department, Nantes University Hospital, Nantes, France
| | - Valérie Ugo
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Pays de la Loire,Hematology Biology, Angers University Hospital, Angers
| | - Mathilde Hunault
- Hematology Clinic, Angers University Hospital, Angers,CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Pays de la Loire
| | - Philippe Moreau
- Hematology Clinic, Nantes University Hospital, Nantes,CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Pays de la Loire
| | - Steven Le Gouill
- Hematology Clinic, Nantes University Hospital, Nantes,CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Pays de la Loire
| | - Patrice Chevallier
- Hematology Clinic, Nantes University Hospital, Nantes,CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Pays de la Loire
| | - Marie C Béné
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Pays de la Loire,Hematology Biology, Nantes University Hospital, Nantes
| | - Yannick Le Bris
- CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Pays de la Loire,Hematology Biology, Nantes University Hospital, Nantes
| |
Collapse
|
19
|
Tondeur S, Paul F, Riou J, Mansier O, Ranta D, Le Clech L, Lippert E, Tavitian S, Chaoui D, Mercier M, De Renzis B, Cottin L, Cassinat B, Chrétien JM, Ianotto JC, Allangba O, Marzac C, Voillat L, Boyer F, Orvain C, Hunault-Berger M, Girodon F, Kiladjian JJ, Ugo V, Luque Paz D. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study. Leukemia 2020; 35:871-875. [PMID: 32694617 DOI: 10.1038/s41375-020-0991-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Revised: 07/09/2020] [Accepted: 07/14/2020] [Indexed: 11/09/2022]
Affiliation(s)
- Sylvie Tondeur
- CHU Grenoble, Laboratoire de Génétique des hémopathies, Institut de Biologie et Pathologie, Grenoble, France.,CNRS UMR 5309, INSERM, U1209, Université Grenoble Alpes, Institute for Advanced Bioscience, Grenoble, France
| | - Franciane Paul
- CHU Montpellier, Service d'Hématologie clinique, Montpellier, France
| | - Jérémie Riou
- Université d'Angers, INSERM 1066 MINT, Angers, France
| | - Olivier Mansier
- CHU de Bordeaux, Laboratoire d'Hématologie et Université de Bordeaux, Inserm U1034, Bordeaux, France
| | - Dana Ranta
- CHU Nancy, Hématologie clinique, Nancy, France
| | | | - Eric Lippert
- CHRU Brest, Laboratoire d'Hématologie, Brest, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.,Université Brest, Inserm, EFS, UMR 1078, GGB, Brest, France
| | - Suzanne Tavitian
- CHU Toulouse, Service d'Hématologie, Toulouse Oncopole, Toulouse, France
| | - Driss Chaoui
- CH Argenteuil, Service d'Hématologie, Argenteuil, France
| | | | - Benoit De Renzis
- CHU Clermont-Ferrand, Hématologie clinique, Clermont-Ferrand, France
| | - Laurane Cottin
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.,CHU Angers, Laboratoire d'hématologie, Angers, France.,Université d'Angers, UFR Santé, Angers, France.,Université d'Angers, Inserm, CRCINA, F-49000, Angers, France
| | - Bruno Cassinat
- APHP, Hôpital Saint Louis, Laboratoire de Biologie Cellulaire, Paris, France
| | - Jean-Marie Chrétien
- CHU Angers, DRCI Cellule de Gestion des Données et Evaluation, Angers, France
| | - Jean-Christophe Ianotto
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.,CHRU Brest, Service d'hématologie clinique, Brest, France
| | | | - Christophe Marzac
- Gustave Roussy, Département de Biologie et Pathologie médicales, Brest, France
| | | | - Françoise Boyer
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.,CHU Angers, Service des maladies du sang, Angers, France
| | - Corentin Orvain
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.,CHU Angers, Service des maladies du sang, Angers, France
| | - Mathilde Hunault-Berger
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.,Université d'Angers, UFR Santé, Angers, France.,Université d'Angers, Inserm, CRCINA, F-49000, Angers, France.,CHU Angers, Service des maladies du sang, Angers, France
| | | | - Jean-Jacques Kiladjian
- APHP, Hôpital Saint Louis, INSERM UMRS 1131, Institut Universitaire d'Hématologie, Paris, France
| | - Valérie Ugo
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.,CHU Angers, Laboratoire d'hématologie, Angers, France.,Université d'Angers, UFR Santé, Angers, France.,Université d'Angers, Inserm, CRCINA, F-49000, Angers, France
| | - Damien Luque Paz
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France. .,CHU Angers, Laboratoire d'hématologie, Angers, France. .,Université d'Angers, UFR Santé, Angers, France. .,Université d'Angers, Inserm, CRCINA, F-49000, Angers, France.
| |
Collapse
|
20
|
Mornet C, Luque Paz D, Lippert E, Galinat H, Mingant F. Detection of intrinsic pathway factor deficiency associated with bleeding risk by kaolin‐based aPTT. Int J Lab Hematol 2020; 42:e107-e109. [DOI: 10.1111/ijlh.13149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 11/22/2019] [Accepted: 12/16/2019] [Indexed: 12/01/2022]
Affiliation(s)
- Clelia Mornet
- CHRU Brest Service d'Hématologie Biologique Brest France
| | | | - Eric Lippert
- CHRU Brest Service d'Hématologie Biologique Brest France
- Université de Bretagne Occidentale INSERM EFS UMR 1078 GGB Brest France
| | - Hubert Galinat
- CHRU Brest Service d'Hématologie Biologique Brest France
| | - Fanny Mingant
- CHRU Brest Service d'Hématologie Biologique Brest France
| |
Collapse
|
21
|
Courtier F, Garnier S, Carbuccia N, Guille A, Adélaide J, Chaffanet M, Hirsch P, Paz DL, Slama B, Vey N, Ugo V, Delhommeau F, Rey J, Birnbaum D, Murati A. Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes Chromosomes Cancer 2020; 59:30-39. [PMID: 31340059 DOI: 10.1002/gcc.22789] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Revised: 06/07/2019] [Accepted: 06/13/2019] [Indexed: 01/24/2023] Open
Abstract
INTRODUCTION In BCR-ABL1-negative myeloproliferative neoplasms, myelofibrosis (MF) is either primary (PMF) or secondary (SMF) to polycythemia vera or essential thrombocythemia. MF is characterized by an increased risk of transformation to acute myeloid leukemia (AML) and a shortened life expectancy. METHODS Because natural histories of PMF and SMF are different, we studied by targeted next generation sequencing the differences in the molecular landscape of 86 PMF and 59 SMF and compared their prognosis impact. RESULTS PMF had more ASXL1 (47.7%) and SRSF2 (14%) gene mutations than SMF (respectively 27.1% and 3.4%, P = .04). Poorer survival was associated with RNA splicing mutations (especially SRSF2) and TP53 in PMF (P = .0003), and with ASXL1 and TP53 mutations in SMF (P < .0001). These mutations of poor prognosis were associated with biological features of scoring systems (DIPSS and MYSEC-PM score). Mutations in TP53/SRSF2 in PMF or TP53/ASXL1 in SMF were more frequent as the risk of these scores increased. This allowed for a better stratification of MF patients, especially within the DIPSS intermediate-1 risk group (DIPSS) or the MYSEC-PM high risk group. AML transformation occurred faster in SMF than in PMF and patients who transformed to AML were more SRSF2-mutated and less CALR-mutated at MF sampling. CONCLUSIONS PMF and SMF have different but not specific molecular profiles and different prognosis depending on the molecular profile. This may be due to differences in disease history. Combining mutations and existing scores should improve prognosis assessment.
Collapse
Affiliation(s)
- Frédéric Courtier
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, Marseille, France.,Département d'Oncologie Prédictive, Institut Paoli-Calmettes (IPC), Marseille, France.,Aix-Marseille Université, Marseille, France
| | - Séverine Garnier
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, Marseille, France.,Département d'Oncologie Prédictive, Institut Paoli-Calmettes (IPC), Marseille, France
| | - Nadine Carbuccia
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, Marseille, France.,Département d'Oncologie Prédictive, Institut Paoli-Calmettes (IPC), Marseille, France
| | - Arnaud Guille
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, Marseille, France.,Département d'Oncologie Prédictive, Institut Paoli-Calmettes (IPC), Marseille, France
| | - José Adélaide
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, Marseille, France.,Département d'Oncologie Prédictive, Institut Paoli-Calmettes (IPC), Marseille, France
| | - Max Chaffanet
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, Marseille, France.,Département d'Oncologie Prédictive, Institut Paoli-Calmettes (IPC), Marseille, France.,Aix-Marseille Université, Marseille, France
| | - Pierre Hirsch
- Centre de Recherche Saint-Antoine CRSA, APHP, Hôpital Saint-Antoine, Sorbonne Université, Inserm, Paris, France
| | | | - Bohrane Slama
- Centre Hospitalier Général d'Avignon, Service d'Onco-Hématologie, France
| | - Norbert Vey
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, Marseille, France.,Aix-Marseille Université, Marseille, France.,Département d'Hématologie, IPC, Marseille, France
| | - Valérie Ugo
- Laboratoire d'Hématologie, CHU d'Angers, Angers, France
| | - François Delhommeau
- Centre de Recherche Saint-Antoine CRSA, APHP, Hôpital Saint-Antoine, Sorbonne Université, Inserm, Paris, France
| | - Jérome Rey
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, Marseille, France.,Département d'Hématologie, IPC, Marseille, France
| | - Daniel Birnbaum
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, Marseille, France.,Département d'Oncologie Prédictive, Institut Paoli-Calmettes (IPC), Marseille, France.,Aix-Marseille Université, Marseille, France
| | - Anne Murati
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, Marseille, France.,Département d'Oncologie Prédictive, Institut Paoli-Calmettes (IPC), Marseille, France.,Département de BioPathologie, IPC, Marseille, France
| |
Collapse
|
22
|
Bouvier A, Riou J, Thépot S, Sutra Del Galy A, François S, Schmidt A, Orvain C, Estienne MH, Villate A, Luque Paz D, Cottin L, Ribourtout B, Beucher A, Delneste Y, Ifrah N, Ugo V, Hunault-Berger M, Blanchet O. Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation. Leukemia 2019; 34:1342-1353. [PMID: 31768015 DOI: 10.1038/s41375-019-0624-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Revised: 10/18/2019] [Accepted: 11/03/2019] [Indexed: 12/20/2022]
Abstract
Relapse is a major complication of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (SCT). The objective of our study was to evaluate chimerism monitoring on the CD3-negative mononuclear cells by RQ-PCR to predict relapse of patients allografted for AML and to compare its performance with WT1 quantification. A cohort of 100 patients undergoing allogenic SCT for AML was retrospectively analyzed in a single institution. Patients without complete chimerism, defined as less than 0.01% of recipient's DNA in CD3-negative cells, had a significantly higher risk of relapse and a lower overall survival (p < 0.001). An increase in the percentage of recipient DNA in CD3-negative cells was associated with an increased risk of relapse (p < 0.001) but not with overall survival. Comparable performances between monitoring of CD3-negative cell chimerism and WT1 expression to predict relapse was observed up to more than 90 days before hematological relapse, with sensitivity of 82% and 78%, respectively, and specificity of 100% for both approaches. Quantitative specific chimerism of the CD3-negative mononuclear fraction, enriched in blastic cells, is a new and powerful tool for monitoring measurable residual disease and could be used for AML patients without available molecular markers.
Collapse
Affiliation(s)
- Anne Bouvier
- CHU Angers, Laboratoire d'Hématologie, Angers, France. .,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France. .,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.
| | - Jérémie Riou
- MINT, UMR INSERM 1066, CNRS 6021, Université d'Angers, Angers, France.,Université d'Angers, UFR Santé, Angers, France
| | - Sylvain Thépot
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Université d'Angers, UFR Santé, Angers, France.,CHU Angers, Service des Maladies du sang, Angers, France
| | | | - Sylvie François
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CHU Angers, Service des Maladies du sang, Angers, France
| | - Aline Schmidt
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Université d'Angers, UFR Santé, Angers, France.,CHU Angers, Service des Maladies du sang, Angers, France
| | - Corentin Orvain
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Université d'Angers, UFR Santé, Angers, France.,CHU Angers, Service des Maladies du sang, Angers, France
| | - Marie-Hélène Estienne
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CHU Tours, Service d'Hématologie biologique, Tours, France
| | - Alban Villate
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CHU Tours, Service d'Hématologie et thérapie cellulaire, Tours, France
| | - Damien Luque Paz
- CHU Angers, Laboratoire d'Hématologie, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Université d'Angers, UFR Santé, Angers, France
| | - Laurane Cottin
- CHU Angers, Laboratoire d'Hématologie, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,Université d'Angers, UFR Santé, Angers, France
| | - Bénédicte Ribourtout
- CHU Angers, Laboratoire d'Hématologie, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Annaëlle Beucher
- CHU Angers, Laboratoire d'Hématologie, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Yves Delneste
- CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,CHU Angers, Laboratoire d'Immunologie et Allergologie, Angers, France
| | - Norbert Ifrah
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Université d'Angers, UFR Santé, Angers, France.,CHU Angers, Service des Maladies du sang, Angers, France
| | - Valérie Ugo
- CHU Angers, Laboratoire d'Hématologie, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Université d'Angers, UFR Santé, Angers, France
| | - Mathilde Hunault-Berger
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Université d'Angers, UFR Santé, Angers, France.,CHU Angers, Service des Maladies du sang, Angers, France
| | - Odile Blanchet
- CHU Angers, Laboratoire d'Hématologie, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Université d'Angers, UFR Santé, Angers, France.,CHU Angers, Centre de Ressources Biologiques, BB-0033-00038, Angers, France
| |
Collapse
|
23
|
Cottin L, Riou J, Orvain C, Ianotto JC, Boyer F, Renard M, Truchan‐Graczyk M, Murati A, Jouanneau‐Courville R, Allangba O, Mansier O, Burroni B, Rousselet MC, Quintin‐Roué I, Martin A, Sadot‐Lebouvier S, Delneste Y, Chrétien J, Hunault‐Berger M, Blanchet O, Lippert E, Ugo V, Luque Paz D. Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. Br J Haematol 2019; 188:935-944. [DOI: 10.1111/bjh.16276] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Accepted: 08/25/2019] [Indexed: 12/13/2022]
|
24
|
Beucher A, Dib M, Orvain C, Bouvier A, Jouanneau‐Courville R, Dobo I, Cottin L, Guardiola P, Rousselet M, Blanchet O, Hunault M, Ugo V, Luque Paz D. Next generation sequencing redefines a triple negative essential thrombocythaemia as double‐positive with rare mutations on
JAK
2
V617 and
MPL
W515 hotspots. Br J Haematol 2019; 186:785-788. [DOI: 10.1111/bjh.15954] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Annaëlle Beucher
- Laboratoire d'Hématologie CHU d'Angers Angers France
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
| | - Mammoun Dib
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
- Service des Maladies du Sang CHU Angers Angers France
| | - Corentin Orvain
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
- Service des Maladies du Sang CHU Angers Angers France
- UFR Santé Université Angers Angers France
- CRCINA, INSERM, Université de Nantes, Université d’Angers Angers France
| | - Anne Bouvier
- Laboratoire d'Hématologie CHU d'Angers Angers France
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
- UFR Santé Université Angers Angers France
- CRCINA, INSERM, Université de Nantes, Université d’Angers Angers France
| | - Rebecca Jouanneau‐Courville
- Laboratoire d'Hématologie CHU d'Angers Angers France
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
| | - Irène Dobo
- Laboratoire d'Hématologie CHU d'Angers Angers France
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
| | - Laurane Cottin
- Laboratoire d'Hématologie CHU d'Angers Angers France
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
- CRCINA, INSERM, Université de Nantes, Université d’Angers Angers France
| | - Philippe Guardiola
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
- UFR Santé Université Angers Angers France
- CRCINA, INSERM, Université de Nantes, Université d’Angers Angers France
- Service de Génomique Onco‐Hématologique (SERGOH) CHU Angers Angers France
| | - Marie‐Christine Rousselet
- UFR Santé Université Angers Angers France
- Département de Pathologie Cellulaire et Tissulaire CHU Angers Angers France
| | - Odile Blanchet
- Laboratoire d'Hématologie CHU d'Angers Angers France
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
- UFR Santé Université Angers Angers France
- CRCINA, INSERM, Université de Nantes, Université d’Angers Angers France
- Centre de Ressources Biologiques CHU Angers Angers France
| | - Mathilde Hunault
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
- Service des Maladies du Sang CHU Angers Angers France
- UFR Santé Université Angers Angers France
- CRCINA, INSERM, Université de Nantes, Université d’Angers Angers France
| | - Valérie Ugo
- Laboratoire d'Hématologie CHU d'Angers Angers France
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
- UFR Santé Université Angers Angers France
- CRCINA, INSERM, Université de Nantes, Université d’Angers Angers France
| | - Damien Luque Paz
- Laboratoire d'Hématologie CHU d'Angers Angers France
- Fédération Hospitalo‐Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL) Angers France
- UFR Santé Université Angers Angers France
- CRCINA, INSERM, Université de Nantes, Université d’Angers Angers France
| |
Collapse
|
25
|
Cottin L, Riou J, Boyer F, Bouvier A, Zannetti A, Blouet A, Truchan-Graczyk M, Jouanneau-Courville R, Beucher A, Ribourtout B, Orvain C, Hunault-Berger M, Blanchet O, Ugo V, Luque Paz D. WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis. Blood Cells Mol Dis 2018; 75:35-40. [PMID: 30612065 DOI: 10.1016/j.bcmd.2018.12.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Revised: 12/17/2018] [Accepted: 12/19/2018] [Indexed: 11/17/2022]
Abstract
Classical Philadelphia-negative myeloproliferative neoplasms include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). They are characterized by the presence of driver mutations of JAK2, CALR or MPL genes. Overexpression of WT1 is used as a marker of minimal residual disease in acute myeloid leukemia, especially after allogeneic stem cell transplantation (SCT). We investigated WT1 expression at diagnosis in 152 MPN patients and showed that the WT1 transcript was overexpressed in PMFs and PVs compared to controls. In particular, WT1 transcript levels were higher in PMF than in ET and PV. WT1 transcript levels were significantly increased during myelofibrotic transformation of ET or PV. Using multivariate linear regression, high WT1 transcript levels in PMF were associated with age over 65, splenomegaly and thrombocytopenia. The ROC curve analysis showed that a level of WT1 transcript >10 WT1 copies/104ABL1 enabled the diagnosis of PMF with a specificity of 95.8% (PMF vs ET; ROC AUC = 0.91). In myelofibrosis, studying follow-ups of WT1 transcript showed that this marker is of interest after allogeneic SCT. These results demonstrate that WT1 overexpression is a simple marker of myelofibrosis in MPN and could be used during patient follow-up.
Collapse
Affiliation(s)
- Laurane Cottin
- Université Angers, UFR Santé, Angers, France; CHU Angers, Laboratoire d'Hématologie, Angers, France; INSERM, CRCINA, Université de Nantes, Université d'Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France
| | - Jérémie Riou
- Université Angers, UFR Santé, Angers, France; INSERM, UMR 1066, CNRS 6021, MINT, Université d'Angers, Angers, France
| | - Françoise Boyer
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France; CHU Angers, Service des Maladies du Sang, Angers, France
| | - Anne Bouvier
- CHU Angers, Laboratoire d'Hématologie, Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France
| | | | | | | | | | | | | | - Corentin Orvain
- Université Angers, UFR Santé, Angers, France; INSERM, CRCINA, Université de Nantes, Université d'Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France; CHU Angers, Service des Maladies du Sang, Angers, France
| | - Mathilde Hunault-Berger
- Université Angers, UFR Santé, Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France; CHU Angers, Service des Maladies du Sang, Angers, France
| | - Odile Blanchet
- Université Angers, UFR Santé, Angers, France; CHU Angers, Laboratoire d'Hématologie, Angers, France; INSERM, CRCINA, Université de Nantes, Université d'Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France; CHU Angers, Centre de ressources biologiques, BB-0033-00038 Angers, France
| | - Valérie Ugo
- Université Angers, UFR Santé, Angers, France; CHU Angers, Laboratoire d'Hématologie, Angers, France; INSERM, CRCINA, Université de Nantes, Université d'Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France
| | - Damien Luque Paz
- Université Angers, UFR Santé, Angers, France; CHU Angers, Laboratoire d'Hématologie, Angers, France; INSERM, CRCINA, Université de Nantes, Université d'Angers, France; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), France.
| |
Collapse
|
26
|
Dumas PY, Mansier O, Prouzet-Mauleon V, Koya J, Villacreces A, Brunet de la Grange P, Luque Paz D, Bidet A, Pasquet JM, Praloran V, Salin F, Kurokawa M, Mahon FX, Cardinaud B, Lippert E. MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms. BMC Cancer 2018; 18:1098. [PMID: 30419846 PMCID: PMC6233495 DOI: 10.1186/s12885-018-4993-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Accepted: 10/24/2018] [Indexed: 11/19/2022] Open
Abstract
Background Atypical Myeloproliferative Neoplasms (aMPN) share characteristics of MPN and Myelodysplastic Syndromes. Although abnormalities in cytokine signaling are common in MPN, the pathophysiology of atypical MPN still remains elusive. Since deregulation of microRNAs is involved in the biology of various cancers, we studied the miRNome of aMPN patients. Methods MiRNome and mutations in epigenetic regulator genes ASXL1, TET2, DNMT3A, EZH2 and IDH1/2 were explored in aMPN patients. Epigenetic regulation of miR-10a and HOXB4 expression was investigated by treating hematopoietic cell lines with 5-aza-2’deoxycytidine, valproic acid and retinoic acid. Functional effects of miR-10a overexpression on cell proliferation, differentiation and self-renewal were studied by transducing CD34+ cells with lentiviral vectors encoding the pri-miR-10a precursor. Results MiR-10a was identified as the most significantly up-regulated microRNA in aMPN. MiR-10a expression correlated with that of HOXB4, sitting in the same genomic locus. The transcription of these two genes was increased by DNA demethylation and histone acetylation, both necessary for optimal expression induction by retinoic acid. Moreover, miR-10a and HOXB4 overexpression seemed associated with DNMT3A mutation in hematological malignancies. However, overexpression of miR-10a had no effect on proliferation, differentiation or self-renewal of normal hematopoietic progenitors. Conclusions MiR-10a and HOXB4 are overexpressed in aMPN. This overexpression seems to be the result of abnormalities in epigenetic regulation mechanisms. Our data suggest that miR-10a could represent a simple marker of transcription at this genomic locus including HOXB4, widely recognized as involved in stem cell expansion. Electronic supplementary material The online version of this article (10.1186/s12885-018-4993-2) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Pierre-Yves Dumas
- CHU de Bordeaux, Hématologie Clinique et Thérapie Cellulaire, F-33000, Bordeaux, France.,INSERM U1035, Université de Bordeaux, Bordeaux, France
| | - Olivier Mansier
- INSERM U1218, Université de Bordeaux, Bordeaux, France.,CHU de Bordeaux, Laboratoire d'Hématologie, F-33000, Bordeaux, France
| | | | - Junji Koya
- Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, bunkyo-ku, Tokyo, 113-8655, Japan
| | | | - Philippe Brunet de la Grange
- Etablissement Français du Sang - Aquitaine Limousin, Laboratoire R&D d'Ingénierie Cellulaire, Université de Bordeaux, Bordeaux, France
| | | | - Audrey Bidet
- CHU de Bordeaux, Laboratoire d'Hématologie, F-33000, Bordeaux, France
| | | | - Vincent Praloran
- INSERM U1035, Université de Bordeaux, Bordeaux, France.,CHU de Bordeaux, Laboratoire d'Hématologie, F-33000, Bordeaux, France
| | - Franck Salin
- INRA, Plateforme Génome Transcriptome de Bordeaux, BIOGECO, UMR 1202, F-33610, Cestas, France
| | - Mineo Kurokawa
- Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, bunkyo-ku, Tokyo, 113-8655, Japan
| | - François-Xavier Mahon
- INSERM U1218, Université de Bordeaux, Bordeaux, France.,Institut Bergonié, Bordeaux, France
| | - Bruno Cardinaud
- INSERM U1218, Université de Bordeaux, Bordeaux, France.,Bordeaux Institut National Polytechnique, F-33000, Bordeaux, France
| | - Eric Lippert
- INSERM U1035, Université de Bordeaux, Bordeaux, France. .,CHU de Bordeaux, Laboratoire d'Hématologie, F-33000, Bordeaux, France. .,CHRU de Brest, Service d'Hématologie Biologique et INSERM U1078, Université de Bretagne Occidentale, Brest, France.
| |
Collapse
|
27
|
Bouvier A, Ribourtout B, François S, Orvain C, Paz DL, Beucher A, Guérard A, Guardiola P, Ugo V, Blanchet O, Geneviève F, Schmidt A, Hunault-Berger M. Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2018; 101:570-574. [PMID: 30007088 DOI: 10.1111/ejh.13143] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Revised: 07/06/2018] [Accepted: 07/06/2018] [Indexed: 12/21/2022]
Abstract
Donor cell leukemia (DCL) is an infrequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). Its true incidence is difficult to assess, although improvements in chimerism studies contributed to a better diagnosis of DCL. We report two rare cases of donor cell-derived acute promyelocytic leukemia (APL). To our knowledge, only two cases have been described in the literature. Here, we report one male and one female patients with acute myeloid leukemia (AML), who developed an APL in donor cells after HSCT. The latency between HSCT and DCL was 279 and 43 months, respectively. Fluorescent in situ hybridation and chimerism monitoring analysis proved the donor origin of APL. Surprisingly, donor lymphocyte infusion provided a hematological response during 19 months in the female patient. The mechanisms associated with pathogenesis of DCL are unclear and seem to be multifactorial. Increasing worldwide allogeneic hematopoietic stem cell transplantation activity and potentially the age of donor could explain the increasing incidence of DCL in the future. It is highlighted that long-term follow up of recipients will allow to report all cases of DCL, to clarify the genetic landscape and factors which contribute to DCL, to understand the response to DLI.
Collapse
Affiliation(s)
- Anne Bouvier
- Laboratoire d'Hématologie, CHU d'Angers, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France
| | - Bénédicte Ribourtout
- Laboratoire d'Hématologie, CHU d'Angers, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Sylvie François
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,Service des maladies du sang, CHU d'Angers, Angers, France
| | - Corentin Orvain
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Service des maladies du sang, CHU d'Angers, Angers, France.,UFR Santé, Université d'Angers, Angers, France
| | - Damien Luque Paz
- Laboratoire d'Hématologie, CHU d'Angers, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,UFR Santé, Université d'Angers, Angers, France
| | - Annaëlle Beucher
- Laboratoire d'Hématologie, CHU d'Angers, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Alexandre Guérard
- Laboratoire d'Hématologie, CHU d'Angers, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,UFR Santé, Université d'Angers, Angers, France
| | - Philippe Guardiola
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Service des maladies du sang, CHU d'Angers, Angers, France.,UFR Santé, Université d'Angers, Angers, France.,Service de Génomique Onco-Hématologique, CHU Angers, Angers, France
| | - Valérie Ugo
- Laboratoire d'Hématologie, CHU d'Angers, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,UFR Santé, Université d'Angers, Angers, France
| | - Odile Blanchet
- Laboratoire d'Hématologie, CHU d'Angers, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,UFR Santé, Université d'Angers, Angers, France.,Centre de ressources biologiques, CHU Angers, Angers, France
| | - Franck Geneviève
- Laboratoire d'Hématologie, CHU d'Angers, Angers, France.,Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France
| | - Aline Schmidt
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Service des maladies du sang, CHU d'Angers, Angers, France.,UFR Santé, Université d'Angers, Angers, France
| | - Mathilde Hunault-Berger
- Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Angers, France.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.,Service des maladies du sang, CHU d'Angers, Angers, France.,UFR Santé, Université d'Angers, Angers, France
| |
Collapse
|
28
|
Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, Boyer F, Conejero C, Fitoussi O, Riou J, Adiko D, Touati M, Chauzeix J, Viallard JF, Béné MC, Giraudier S, Ugo V, Lippert E. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol 2018; 93:E84-E86. [PMID: 29266414 DOI: 10.1002/ajh.25014] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Revised: 12/16/2017] [Accepted: 12/18/2017] [Indexed: 01/23/2023]
Affiliation(s)
- Olivier Mansier
- UFR Sciences de la Vie et de la Santé; Université de Bordeaux; Bordeaux France
- CHU de Bordeaux, Laboratoire d'Hématologie; Bordeaux France
- INSERM U1218, ACTION, Université de Bordeaux; Bordeaux France
| | - Damien Luque Paz
- Université Angers, UFR Santé; Angers France
- CHU d'Angers, Laboratoire d'Hématologie; Angers France
- CRCINA, INSERM, Université d'Angers; Angers France
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL); Angers France
| | - Jean-Christophe Ianotto
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL); Angers France
- CHU de Brest, Service d'Hématologie Clinique; Brest France
| | - Yannick Le Bris
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL); Angers France
- CHU de Nantes, Laboratoire d'Hématologie; Nantes France
| | - Aurélie Chauveau
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL); Angers France
- CHU de Brest, Laboratoire d'Hématologie; Brest France
- INSERM U1078, CHRU Brest; Brest France
- Université de Bretagne Occidentale, UFR Médecine; Brest France
| | - Françoise Boyer
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL); Angers France
- CHU d'Angers, Service des Maladies du Sang; Angers France
| | - Carole Conejero
- AP-HP, CHU Henri Mondor, Laboratoire d'Hématologie; Créteil France
| | - Olivier Fitoussi
- Polyclinique Bordeaux Nord Aquitaine, Service d'hémato-oncologie; Bordeaux France
| | - Jérémie Riou
- INSERM 1066 MINT, Université d'Angers; Angers France
| | - Didier Adiko
- Service de Médecine-Hématologie; CH Robert Boulin; Libourne France
| | | | - Jasmine Chauzeix
- CHU de Limoges, Laboratoire d'Hématologie, CRBS; Limoges France
- UMR CNRS 7276; Limoges France
| | | | - Marie C. Béné
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL); Angers France
- CHU de Nantes, Laboratoire d'Hématologie; Nantes France
| | | | - Valérie Ugo
- Université Angers, UFR Santé; Angers France
- CHU d'Angers, Laboratoire d'Hématologie; Angers France
- CRCINA, INSERM, Université d'Angers; Angers France
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL); Angers France
| | - Eric Lippert
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL); Angers France
- CHU de Brest, Laboratoire d'Hématologie; Brest France
- INSERM U1078, CHRU Brest; Brest France
- Université de Bretagne Occidentale, UFR Médecine; Brest France
| |
Collapse
|
29
|
Luque Paz D, Boyer F, Beucher A, Bouvier A, Jouanneau-Courville R, Guardiola P, Lambert D, Delneste Y, Hunault M, Blanchet O, Ugo V. Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis. Blood Cells Mol Dis 2018; 71:75-76. [PMID: 29703677 DOI: 10.1016/j.bcmd.2018.04.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Accepted: 04/21/2018] [Indexed: 10/17/2022]
Affiliation(s)
- Damien Luque Paz
- CHU Angers, Laboratoire d'Hématologie, Institut de Biologie en Santé, Angers, France; Université d'Angers, UFR Santé, Angers, France; CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France; Fédération Hospitalo-Universitaire (FHU) GOAL, 'Grand Ouest Against Leukemia', France
| | | | - Annaëlle Beucher
- CHU Angers, Laboratoire d'Hématologie, Institut de Biologie en Santé, Angers, France
| | - Anne Bouvier
- CHU Angers, Laboratoire d'Hématologie, Institut de Biologie en Santé, Angers, France; CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France; Fédération Hospitalo-Universitaire (FHU) GOAL, 'Grand Ouest Against Leukemia', France
| | - Rebecca Jouanneau-Courville
- CHU Angers, Laboratoire d'Hématologie, Institut de Biologie en Santé, Angers, France; Fédération Hospitalo-Universitaire (FHU) GOAL, 'Grand Ouest Against Leukemia', France
| | - Philippe Guardiola
- Université d'Angers, UFR Santé, Angers, France; CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France; Fédération Hospitalo-Universitaire (FHU) GOAL, 'Grand Ouest Against Leukemia', France; CHU Angers, Service de Génomique Onco-Hématologique, Angers, France
| | - Diane Lambert
- CHU Angers, Service de Génomique Onco-Hématologique, Angers, France
| | - Yves Delneste
- CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France
| | - Mathilde Hunault
- Université d'Angers, UFR Santé, Angers, France; CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France; Fédération Hospitalo-Universitaire (FHU) GOAL, 'Grand Ouest Against Leukemia', France; CHU Angers, Service des Maladies du Sang, Angers, France
| | - Odile Blanchet
- CHU Angers, Laboratoire d'Hématologie, Institut de Biologie en Santé, Angers, France; Université d'Angers, UFR Santé, Angers, France; CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France; Fédération Hospitalo-Universitaire (FHU) GOAL, 'Grand Ouest Against Leukemia', France; CHU Angers, Centre de Ressources Biologiques, BB-0033-00038, Angers, France
| | - Valérie Ugo
- CHU Angers, Laboratoire d'Hématologie, Institut de Biologie en Santé, Angers, France; Université d'Angers, UFR Santé, Angers, France; CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France; Fédération Hospitalo-Universitaire (FHU) GOAL, 'Grand Ouest Against Leukemia', France.
| |
Collapse
|
30
|
Paz DL, Delluc A, Tromeur C, Couturier MA, Gouillou M, Berthou C, Mottier D, Ugo V, Ianotto JC, Chauveau A. Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism. Thromb Haemost 2017; 115:225-6. [DOI: 10.1160/th15-02-0134] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 06/23/2015] [Indexed: 11/05/2022]
|
31
|
Luque Paz D, Chauveau A, Boyer F, Buors C, Samaison L, Cottin L, Seegers V, Férec C, Le Maréchal C, Gueguen P, Lippert E, Ianotto JC, Ugo V. Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. Genes Chromosomes Cancer 2017; 56:354-362. [DOI: 10.1002/gcc.22437] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Revised: 12/02/2016] [Accepted: 12/03/2016] [Indexed: 12/29/2022] Open
Affiliation(s)
- Damien Luque Paz
- CHU Angers, Laboratoire d'Hématologie; Angers France
- Université d'Angers, UFR Santé; Angers France
- INSERM Unité 892, CNRS Unit 6299; Angers France
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL)
| | - Aurélie Chauveau
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL)
- CHU Brest, Laboratoire d'Hématologie; Brest France
- Université de Brest, Bretagne Occidentale, UFR Médecine; Brest France
- INSERM Unité 1078, CHRU Brest; Brest France
| | - Françoise Boyer
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL)
- CHU Angers, Service des Maladies du Sang; Angers France
| | - Caroline Buors
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL)
- CHU Brest, Laboratoire d'Hématologie; Brest France
| | | | - Laurane Cottin
- CHU Angers, Laboratoire d'Hématologie; Angers France
- Université d'Angers, UFR Santé; Angers France
- INSERM Unité 892, CNRS Unit 6299; Angers France
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL)
| | - Valérie Seegers
- Université d'Angers, UFR Santé; Angers France
- INSERM Unité 892, CNRS Unit 6299; Angers France
- Département de Statistique; Institut de Cancérologie de l'Ouest; Angers France
| | - Claude Férec
- Université de Brest, Bretagne Occidentale, UFR Médecine; Brest France
- INSERM Unité 1078, CHRU Brest; Brest France
- CHU Brest, Laboratoire de Génétique; Brest France
| | - Cédric Le Maréchal
- Université de Brest, Bretagne Occidentale, UFR Médecine; Brest France
- INSERM Unité 1078, CHRU Brest; Brest France
- CHU Brest, Laboratoire de Génétique; Brest France
| | - Paul Gueguen
- Université de Brest, Bretagne Occidentale, UFR Médecine; Brest France
- INSERM Unité 1078, CHRU Brest; Brest France
- CHU Brest, Laboratoire de Génétique; Brest France
| | - Eric Lippert
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL)
- CHU Brest, Laboratoire d'Hématologie; Brest France
- Université de Brest, Bretagne Occidentale, UFR Médecine; Brest France
- INSERM Unité 1078, CHRU Brest; Brest France
| | - Jean-Christophe Ianotto
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL)
- CHU Brest, Service d'Hématologie Clinique; Brest France
| | - Valérie Ugo
- CHU Angers, Laboratoire d'Hématologie; Angers France
- Université d'Angers, UFR Santé; Angers France
- INSERM Unité 892, CNRS Unit 6299; Angers France
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL)
| |
Collapse
|
32
|
Chauveau A, Nibourel O, Tondeur S, Luque Paz D, Mansier O, Paul F, Wemeau M, Preudhomme C, Lippert E, Ugo V. Absence of CALR mutations in JAK2-negative polycythemia. Haematologica 2017; 102:e15-e16. [PMID: 27758825 PMCID: PMC5210252 DOI: 10.3324/haematol.2016.154799] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Affiliation(s)
| | | | | | | | | | | | | | | | - Eric Lippert
- CHRU Brest, Service d'Hématologie Biologique, France
| | - Valérie Ugo
- CHU Angers, Laboratoire d'Hématologie, France
| |
Collapse
|
33
|
Luque Paz D, Ianotto JC, Chauveau A, Guibourg B, Lecucq L, Lippert E, Ugo V. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib. Ann Hematol 2016; 95:349-50. [DOI: 10.1007/s00277-015-2518-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Accepted: 09/29/2015] [Indexed: 11/29/2022]
|
34
|
Chauveau A, Luque Paz D, Lecucq L, Le Gac G, Le Maréchal C, Gueguen P, Berthou C, Ugo V. A new point mutation in EPOR inducing a short deletion in congenital erythrocytosis. Br J Haematol 2015; 172:475-7. [PMID: 26010769 DOI: 10.1111/bjh.13511] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- Aurélie Chauveau
- CHU Brest, Laboratoire d'Hématologie, Brest, France.,Université de Brest, UFR Médecine, Brest, France.,INSERM U1078, Brest, France
| | - Damien Luque Paz
- CHU Brest, Laboratoire d'Hématologie, Brest, France.,INSERM U1078, Brest, France
| | - Lydie Lecucq
- CHU Brest, Laboratoire d'Hématologie, Brest, France.,Plateforme INCa de Génétique Hospitalière des Cancers de Brest, Brest, France
| | - Gérald Le Gac
- Université de Brest, UFR Médecine, Brest, France.,INSERM U1078, Brest, France.,CHU Brest, Laboratoire de Génétique, Brest, France
| | - Cédric Le Maréchal
- Université de Brest, UFR Médecine, Brest, France.,INSERM U1078, Brest, France.,CHU Brest, Laboratoire de Génétique, Brest, France
| | - Paul Gueguen
- Université de Brest, UFR Médecine, Brest, France.,INSERM U1078, Brest, France.,CHU Brest, Laboratoire de Génétique, Brest, France
| | - Christian Berthou
- Université de Brest, UFR Médecine, Brest, France.,CHU Brest, Service d'Hématologie, Institut de Cancérologie et d'Hématologie, Brest, France
| | - Valérie Ugo
- CHU Brest, Laboratoire d'Hématologie, Brest, France. .,Université de Brest, UFR Médecine, Brest, France. .,INSERM U1078, Brest, France.
| |
Collapse
|